NASDAQ:CNSP

CNS Pharmaceuticals Q1 2026 Earnings Results & Report

CNS Pharmaceuticals logo
$4.26 +0.11 (+2.67%)
Closing price 03:58 PM Eastern
Extended Trading
$4.26 0.00 (-0.02%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CNS Pharmaceuticals beat analyst earnings expectations in its Q1 2026 results, released May 14, 2026. The company reported EPS of -$7.30 versus the -$8.82 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
After Market Closes
Conference Call
7:00 AM ET

CNS Pharmaceuticals EPS Results

Actual EPS
-$7.30
Consensus EPS
-$8.82
Beat/Miss
Beat by +$1.52
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 6 quarters

CNS Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

CNS Pharmaceuticals Q1 2026 Earnings FAQ

CNS Pharmaceuticals (NASDAQ:CNSP) reported earnings of -$7.30 per share for Q1 2026, beating the consensus estimate of -$8.82. The report was announced on Thursday, May 14, 2026.

CNS Pharmaceuticals Earnings Headlines

URGENT: If you own a home, please review the map below.
More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards urges homeowners to check the map and see whether one is near them. Families in Georgia have been forced to sell, entire Ohio neighborhoods are being torn down, and nearly 50,000 Lake Tahoe residents face losing power. Rickards advised the Pentagon and the U.S. intelligence community for decades. He says one man outside Washington can stop it.tc pixel
See More CNS Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CNS Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CNS Pharmaceuticals and other key companies, straight to your email.

About CNS Pharmaceuticals

CNS Pharmaceuticals (NASDAQ:CNSP) is a biopharmaceutical company focused on developing treatments for cancers of the brain and central nervous system. Its research has centered on investigational therapies intended to address the challenges of treating tumors that affect these areas.

The company’s lead candidate has been berubicin, an experimental anthracycline designed to cross the blood-brain barrier. CNS Pharmaceuticals has evaluated berubicin for glioblastoma, an aggressive form of brain cancer. The drug remains investigational and is not an approved treatment.

The company has also pursued other experimental compounds for brain and central nervous system conditions. Its work has included clinical development and research; it does not market an established portfolio of approved medicines.

View CNS Pharmaceuticals Profile